Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.

被引：2
|
作者：
Meador, Catherine B. [1 ]
Jin, Hailing [1 ]
de Stanchina, Elisa [2 ]
Pirazzoli, Valentina [3 ]
Ladanyi, Marc [2 ]
Wang, Lu [2 ]
Chen, Xi [1 ]
Eisenberg, Rosana [1 ]
Cross, Darren [4 ]
Pao, William [1 ]
机构：
[1] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
[2] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
[3] Yale Univ, Sch Med, New Haven, CT USA
[4] AstraZeneca Oncol Innovat Med, Macclesfield, Cheshire, England
来源：
CLINICAL CANCER RESEARCH | 2014年 / 20卷
关键词：
D O I：
10.1158/1078-0432.14AACRIASLC-B10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B10
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
    Gilbert, Judith A.
    [J]. LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
  • [2] Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas
    Pirazzoli, Valentina
    Takezawa, Ken
    de Stanchina, Elisa
    Pao, William
    Politi, Katerina
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (10)
  • [3] Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
    Pirazzoli, Valentina
    Nebhan, Caroline
    Song, Xiaoling
    Wurtz, Anna
    Walther, Zenta
    Cai, Guoping
    Zhao, Zhongming
    Jia, Peilin
    de Stanchina, Elisa
    Shapiro, Erik M.
    Gale, Molly
    Yin, Ruonan
    Horn, Leora
    Carbone, David P.
    Stephens, Philip J.
    Miller, Vincent
    Gettinger, Scott
    Pao, William
    Politi, Katerina
    [J]. CELL REPORTS, 2014, 7 (04): : 999 - 1008
  • [4] Acquired ALK Rearrangement in EGFR-Mutant Lung Adenocarcinoma Treated with EGFR TKIs
    Wang, Q.
    Chen, R.
    Kang, J.
    Chen, H.
    Wang, B.
    Wang, Z.
    Zhou, Q.
    Wu, Y.
    Yang, J.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S569 - S570
  • [5] Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
    Cortot, Alexis B.
    Moro-Sibilot, Denis
    Cadranel, Jacques
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1827 - 1827
  • [6] Acquired Resistance to Afatinib in EGFR- Mutant Lung Cancer
    Sequist, L. V.
    Gerber, D. E.
    Fidias, P.
    Shaw, A. T.
    Temel, J. S.
    Heist, R. S.
    Gainor, J. F.
    Fulton, L.
    Kennedy, E. A.
    Muzikansky, A.
    Engelma, J. A.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S43 - S44
  • [7] High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells
    Nanjo, Shigeki
    Ebi, Hiromichi
    Arai, Sachiko
    Takeuchi, Shinji
    Yamada, Tadaaki
    Mochizuki, Satsuki
    Okada, Yasunori
    Nakada, Mitsutoshi
    Murakami, Takashi
    Yano, Seiji
    [J]. ONCOTARGET, 2016, 7 (04) : 3847 - 3856
  • [8] Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors
    Landi, Lorenza
    Tiseo, Marcello
    Chiari, Rita
    Ricciardi, Serena
    Rossi, Elisa
    Galetta, Domenico
    Novello, Silvia
    Milella, Michele
    D'Incecco, Armida
    Minuti, Gabriele
    Tibaldi, Carmelo
    Salvini, Jessica
    Facchinetti, Francesco
    Haspinger, Eva Regina
    Cortinovis, Diego
    Santo, Antonio
    Banna, Giuseppe
    Catino, Annamaria
    GiajLevra, Matteo
    Crino, Lucio
    de Marinis, Filippo
    Cappuzzo, Federico
    [J]. CLINICAL LUNG CANCER, 2014, 15 (06) : 411 - 417
  • [9] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Laurila, Niina
    Koivunen, Jussi P.
    [J]. MEDICAL ONCOLOGY, 2015, 32 (07)
  • [10] EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
    Niina Laurila
    Jussi P. Koivunen
    [J]. Medical Oncology, 2015, 32
12345